Graham Capital Management, L.P. Kymera Therapeutics, Inc. Transaction History

Graham Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$22.9 - $43.57 $142,827 - $271,746	-6,237 Reduced 45.22%	7,557 $303,000
Q4 2023 Feb 14, 2024	BUY	$10.97 - $26.84 $151,320 - $370,230	13,794 New	13,794 $351,000
Q2 2023 Aug 14, 2023	BUY	$22.4 - $34.92 $578,816 - $902,332	25,840 New	25,840 $594,000
Q3 2022 Nov 14, 2022	BUY	$20.91 - $34.27 $1.47 Million - $2.41 Million	70,238 Added 228.32%	101,001 $2.2 Million
Q2 2022 Aug 15, 2022	BUY	$14.13 - $42.55 $248,843 - $749,348	17,611 Added 133.9%	30,763 $605,000
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $464,265 - $850,671	13,152 New	13,152 $556,000

210

71.8M

168K

39.4K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.18B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.